Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. immuunijärjestelmää on osoitettu 1 viikon kuluttua rihotrakeiitti-, kalicivirus- ja chlamydophila felis -komponenttien ensisijaisesta rokotuskurssista. immuniteetin kesto on yksi vuosi viimeisen (uudelleen) rokottamisen jälkeen.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immuniteettia on osoitettu viikon kuluttua rhinotracheiitin, kalikiviruksen, chlamydophila felisin ja panleukopenia -komponenttien ensisijaisesta rokotuskurssista. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologisia valmisteita varten felidae, - kissat - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

zoetis belgium sa - sevofluraani - anestesia, yleiset - dogs; cats - anestesian induktioon ja ylläpitoon koirilla ja kissoilla.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing limited - sevofluraani - anestesia, yleiset - dogs; cats - anestesian induktioon ja ylläpitoon.

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

zoetis belgium sa - selamektiini - loisten ja hyönteisten häätöön tarkoitetut valmisteet, endectocides, macrocyclic laktonit, - dogs; cats - kissat ja koirat: hoito ja ennaltaehkäisy kirpputartuntojen aiheuttama ctenocephalides spp. kuukauden kuluttua yksittäisestä hallinnosta. tämä johtuu tuotteen aikuisidos-, larvicidal- ja ovicidal-ominaisuuksista. tuote on munasarjaton 3 viikon ajan annostelun jälkeen. vähentämällä kirppu väestöstä, kuukausittain hoito raskaana oleville ja imettäville eläimille auttaa myös ehkäisyssä kirpputartuntojen pentueen jopa seitsemän viikon iässä. tuotetta voidaan käyttää osana kirppuallergisen ihottuman hoitostrategiaa ja sen munasarjat ja larvicidiset vaikutukset voivat auttaa valvomaan olemassa olevia ympäristölupakasvaimia alueilla, joihin eläimellä on pääsy. dirofilaria immitis -bakteerin aiheuttama sydämen leviämisen ehkäisy kuukausittain. linnake voidaan turvallisesti antaa eläimille on aikuisten sydänmatojen aiheuttama tartunta, kuitenkin, se on suositeltavaa mukaisesti hyvä eläinlääkärin käytäntö, että kaikki yli 6 kuukauden ikäiset eläimet tai enemmän asuvat maissa, joissa vektori on olemassa, testataan sydänmatotartunnan varalta, ennen kuin stronghold-lääkityksen aloittamista. se on myös suositeltavaa, että koirat tulisi testata säännöllisesti aikuisten sydänmatojen infektioita, kuten olennainen osa heartworm ehkäisy-strategiaa, vaikka linnake on annettu kuukausittain. tämä tuote ei ole tehokasta aikuista d vastaan. immitikseen. korvasirujen hoito (otodectes cynotis). kissat:väivetartuntojen hoito tartuntoja (felicola subrostratustreatment aikuisten suolinkaisten (toxocara cati)hoito aikuisten hakamatojen (ancylostoma tubaeforme). koirat:väivetartuntojen hoito (trichodectes canis)syyhypunkkitartuntojen hoito (aiheuttaja sarcoptes scabiei)hoitoon aikuisen suoliston suolinkaisten (toxocara canis)..

Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

bayer ag - rivaroksabaani - arthroplasty, replacement; venous thromboembolism - antitromboottiset aineet - xarelto-valmistetta, samanaikaisesti asetyylisalisyylihapon (asa) yksin tai yhdessä asa plus klopidogreeli tai tiklopidiini, on tarkoitettu aterotromboottisten tapahtumien estämiseen aikuispotilaille, kun akuutti koronaarioireyhtymä (acs) kanssa sydänperäisten biomerkkiaineiden kohoamista. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. laskimotromboembolian (vte) ehkäisy aikuisilla potilailla, jotka saavat elektiivisen lonkan tai polven korvaavan leikkauksen. hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.